Navigation Links
DAIICHI SANKYO EUROPE GmbH Selects DATATRAK eClinical™ for Pan-European Systolic Hypertension Study
Date:8/2/2010

CLEVELAND, Aug. 2 /PRNewswire-FirstCall/ -- DATATRAK International, Inc. (OTCQX: DATA), a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced that DAIICHI SANKYO EUROPE GmbH has selected DATATRAK's eClinical™ platform for a cardiovascular clinical study encompassing 80 sites and 1,200 patients across Europe. Reaping the benefits of a unified platform, DAIICHI SANKYO EUROPE GmbH will utilize DATATRAK's Electronic Data Capture solution in addition to web-based Patient Randomization, Drug Inventory Management, Lab Import and Auto-Coding Engine solutions. Also, study users will be able to view, manage and report on patient data via DATATRAK's dynamic, ad-hoc reporting module. As with all studies for this sponsor, DATATRAK will be producing CDISC SDTM compliant exports throughout the study.

"We have decided to use DATATRAK because the unified platform appealed to our needs. The ease in which for example IWRS or study drug management can be utilized with EDC within one solution will bring us significant benefit throughout the study. Furthermore, the built-in data export routines to SDTM and flexible ad-hoc reporting tools supporting our efforts in process control," said Paul-Egbert Reimitz, Director of Biostatistics and Data Operations at DAIICHI SANKYO EUROPE GmbH.

"We are delighted to have been awarded this new study by DAIICHI SANKYO EUROPE, whose adoption of DATATRAK ONE™ is a testament to both teams' hard work and success in implementing complex international clinical trials," said Laurence P. Birch, DATATRAK's Chairman of the Board. "We remain focused on providing our clients the benefits of increased patient safety, real-time data availability
'/>"/>

SOURCE DATATRAK International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB
2. Daiichi Sankyo, Inc. Names Dr. Jay Feingold Vice President, Medical Affairs
3. Mergent, Inc. Announces Changes to the HealthShares(TM) European Drugs Index
4. CV Therapeutics Receives European Approval for the Brand Name Ranexa(R)
5. Vascular Biogenics Ltd. Presented With the Frost & Sullivan 2008 European Gene Expression Targeting Platform Technology Innovation Award
6. ApoA-I Data Presented at European Society of Cardiology Congress
7. Trubion Pharmaceuticals Wins Patent Opposition - Genentech / Biogen Idec European Patent Revoked
8. CV Therapeutics Announces License Agreement for Ranexa(R) in Europe With Menarini Group
9. Quark Pharmaceuticals Announces Poster Presentations at RNAi Europe 2008
10. BioMS Medical to present at Sachs Associates Biotech in Europe Forum
11. Kuvan Receives Positive Opinion From CHMP for European Approval
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 20, 2014 The report, ... Oligos, Enzymes, Cloning kits), Technology (Bioinformatics, Nanotechnology, ... Pharmaceuticals, Biomaterials, Bioremediation) - Global Forecast to ... drivers, threats, opportunities, and challenges. , Browse ... spread through 185 pages and in-depth TOC ...
(Date:11/21/2014)... (PRWEB) November 21, 2014 Why did ... makes Albert Einstein so instantly recognizable? Why have they ... mathematician, astronomer and author Hilton Ratcliffe seeks out the ... nothing at all to do with science. In " ... Publishing , November 21, 2014), Ratcliffe puts it plainly: ...
(Date:11/21/2014)... 2014 Polaris Group announced today that ... Phase 1 trial of ADI-PEG 20 in combination ... malignant pleural mesothelioma (MPM) and non-squamous non-small cell ... on ADI-PEG 20, both as monotherapy and in ... several other indications, including breast cancer, melanomas, ovarian ...
(Date:11/21/2014)... GUELPH, ON , Nov. 20, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: ... month and nine month periods ended September 30, 2014.  Biorem,s complete ... SEDAR ( www.sedar.com ). Financial Summary:Three-months ended ... CDN$,000 except per share data) , 2014 , ... , 2,282 , 5,281 , 6,715 ...
Breaking Biology Technology:Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 2Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 3Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 4“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 2“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 3“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 4Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2Biorem Reports Third Quarter Results 2Biorem Reports Third Quarter Results 3
... , CALGARY and BLENHEIM, Ontario, Nov. 24 Dow ... Hyland Seeds, a division of Thompsons Limited of Blenheim, Ontario. ... current seeds business as the company anticipates the introduction of ... Dow AgroSciences Herbicide Tolerant Trait Technology in corn in 2012. ...
... , , ST. LOUIS, Nov. 24 ... NASDAQ OMX conference on Tuesday, December 1st at 1:45 PM GMT in ... over the Internet available at http://inve s tor.sig ... can click the "Webcast" icon to access this file. , ...
... , ... November 24 deCODE,genetics, Inc. (Nasdaq: DCGN ) today announced the approval ... the District of Delaware,(the "Bankruptcy Court"). deCODE last week filed a voluntary ... the,Bankruptcy Court. , The orders issued by the ...
Cached Biology Technology:Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 2Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 3deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3
(Date:11/3/2014)... low birth weight and preterm birth are linked to ... Findings published in the American College of Rheumatology (ACR) ... low birth weight and pre-term babies were not at ... adults. , According to the ACR, 27 million ... clinical OA. Symptoms of OA range from mild to ...
(Date:11/2/2014)... LA (2 November 2014)—In support of a bold quest ... & Melinda Gates Foundation today announced an award of ... Vaccine Initiative (MVI) in building new vaccines that will ... realize the "accelerating to zero" agenda. Such vaccines would ... could be called an "immunological bed net." , ...
(Date:11/2/2014)... Silver and Richard Feynman walk into a bar and bump ... sound like the setup to some late-night nerd sketch, researchers ... cumbersome problem in modern biology, namely, finding meaning in the ... the data comprisesreams of cancer mutations that genome-wide studies are ... and efficient ways to parse the signal from the noise ...
Breaking Biology News(10 mins):Preterm, low birth-weight babies may need new hips in adulthood 2New malaria vaccines to prevent infection and block transmission get a shot in the arm 2New malaria vaccines to prevent infection and block transmission get a shot in the arm 3New malaria vaccines to prevent infection and block transmission get a shot in the arm 4Mutant models 2Mutant models 3Mutant models 4
... Liverpool scientists claim that the degeneration of sight, caused by ... 20% by increasing the amount of fruit, vegetables and nuts ... leading cause of blindness in the UK, with 45% of ... condition results in a gradual loss of central vision, due ...
... San Antonio (UTSA) announced today it will receive $500,000 ... five years to develop a unique Graduate Program Initiative ... proposals received by the UT System from its nine ... and only two were awarded to academic institutions. ...
... have long been a favorite of gardeners, but they often ... on organics has more home gardeners concerned about the environment ... Texas A&M University led a study comparing several varieties of ... certain conditions. The results were published in the American Society ...
Cached Biology News:Diet could reduce onset of eye disease by 20 percent 2UTSA wins $500,000 to develop biosensor and regenerative medicine Ph.D. program 2
Phospho-FAK (Tyr576/577) Antibody...
Zinc finger MYM-type protein 3 (Zinc finger protein 261) (DXS6673E protein). [Source:Uniprot/SWISSPROT;Acc:Q14202] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Rabbit polyclonal to Leucyl tRNA synthetase ( Abpromise for all tested applications). Antigen: L930-H1176 denatured human recombinant LRS. Entrez Gene ID: 3926 Swiss Protein ID: Q9P2J5...
WNV Core Antibody...
Biology Products: